Figure 4.

Comparison of primary tumors and metastases in PD-L1-positive patients using [⁸⁹Zr]Zr-DFO-KN035 immunoPET before and after treatment. (A) Representative (Case No. 1) CT and PET/CT images of the layers of primary focus (first row), lymph node metastasis (second row), and bone metastasis (third row, lumbar vertebra 2) sites in a patient with PD-L1-positive cancer (lung primary cancer with bone, lymph node, and brain metastasis) acquired by using [⁸⁹Zr]Zr-DFO-KN035 tracer before (56 h) and after (54 h) antitumor therapy. Red arrows show the locations of primary tumor and metastasis focus sites. (B) Statistical chart and comparison of the long diameters and the radioactive uptake values (SUVmax) of the primary and metastatic tumors in PET molecular imaging with [⁸⁹Zr]Zr-DFO-KN035 before (56 h) and after (54 h) treatment. Data are expressed as the mean ± SD, and n = 3-7 for each site. Paired samples t-test was conducted. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. pretreatment group.